Cholangiocarcinoma Market Regional Analysis:
North America Market Insights
North America industry is predicted to hold largest revenue share of 35% by 2035, impelled by approval of new drugs in the region. The growth of the market in the region is due to the growing small and medium-sized businesses that are engaging in R&D to build medical healthcare facilities in the healthcare sector. In addition, people's eating and lifestyle habits are changing, and bile cancer is becoming more common in the area. Every year, about 8,000 Americans receive a diagnosis for it. The growth of the market in this region is result of new medications being approved for sale. A kinase inhibitor called infigratinib, for example, received accelerated approval from the U.S. FDA in May 2021 for adults with previously treated, incurable locally advanced or metastatic cholangiocarcinoma that has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as identified by an FDA-approved test.
APAC Market Insights
Cholangiocarcinoma market in the Asia Pacific region is projected to account for 25% of the revenue share by 2035. The growth of the market in this region is because cholangiocarcinoma is becoming more and more popular. The expansion of the market is aided by the rise in awareness campaigns and private investment.
